Flutamide withdrawal syndrome is characterized by a decrease in prostate-specific antigen
(PSA) after flutamide withdrawal in a subset of patients with progressing metastatic …

Background. Flutamide withdrawal has been reported to be therapeutically efficacious for
patients with hormone‐refractory prostate cancer, with a reported prostate specific antigen …

PURPOSE To evaluate the effect of discontinuation of the antiandrogen, flutamide, in
patients with metastatic prostate cancer who are progressing on hormonal therapy …

Post-therapy changes in prostate specific antigen (PSA) have been proposed as a surrogate
end point for response in clinical trials of patients with hormone refractory prostatic cancer …

Backgroound The best treatment for patients with “hormone-refractory” metastatic prostate
cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed …

METHODS All patients were required to give informed consent prior to participation in this
protocol. Histologic diagnosis of prostate cancer was confinned at our in-stitution before …

The effect of flutamide withdrawal was studied in 40 patients with stage D2 prostate cancer
showing progression of the disease after an initial and long (average 3.9 years) period of …

PURPOSE: We confirmed the reported rate of prostate specific antigen (PSA) suppression
after flutamide withdrawal in patients with metastatic prostatic carcinoma, increasing serum …

In 1989 the unanticipated agonist effect of antiandrogens on LNCaP prostate cancer cells
was detected. A “flutamide withdrawal syndrome” was first described by Kelly and Scher 15 …

Clinically significant responses after withdrawal of flutamide in patients with hormone-
refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome …